Patents by Inventor Bret E Huff

Bret E Huff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6429317
    Abstract: The present invention provides novel indane-like compounds which can be useful for treating psychosis and other conditions associated with the modulation of a muscarinic receptor. The invention provides formulations and methods for using the novel compounds.
    Type: Grant
    Filed: September 5, 2000
    Date of Patent: August 6, 2002
    Assignee: Eli Lilly and Company
    Inventors: Sean P. Hollinshead, Michael A. Staszak, John S. Ward, Joseph W. Wilson, Bret E. Huff, Philip F. Hughes, Jose S. Mendoza, Charles H. Mitch
  • Patent number: 6211364
    Abstract: The present invention provides intermediate for the preparation of indane-like compounds which are useful for the modulation of a muscarinic receptor.
    Type: Grant
    Filed: June 10, 1999
    Date of Patent: April 3, 2001
    Assignee: Eli Lilly and Company
    Inventors: Bret E Huff, Michael A Staszak, John S Ward
  • Patent number: 5977062
    Abstract: The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity against a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: November 2, 1999
    Assignee: Eli Lilly and Company
    Inventors: Robin D. G. Cooper, Bret E. Huff, Thalia I. Nicas, John T. Quatroche, Michael J. Rodriguez, Nancy J. Snyder, Michael A. Staszak, Richard C. Thompson, Stephen C. Wilkie, Mark J. Zweifel
  • Patent number: 5843889
    Abstract: The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity aginst a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.
    Type: Grant
    Filed: March 12, 1997
    Date of Patent: December 1, 1998
    Assignee: Eli Lilly and Company
    Inventors: Robin D. G. Cooper, Bret E. Huff, Thalia I. Nicas, John T. Quatroche, Michael J. Rodriguez, Nancy J. Snyder, Michael A. Staszak, Richard C. Thompson, Stephen C. Wilkie, Mark J. Zweifel
  • Patent number: 5840684
    Abstract: The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity against a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: November 24, 1998
    Assignee: Eli Lilly and Company
    Inventors: Robin D. G. Cooper, Bret E. Huff, Thalia I. Nicas, John T. Quatroche, Michael J. Rodriguez, Nancy J. Snyder, Michael A. Staszak, Richard C. Thompson, Stephen C. Wilkie, Mark J. Zweifel
  • Patent number: 5530009
    Abstract: This invention provides novel compound of the formula ##STR1## which is neurokinin receptor antagonist.
    Type: Grant
    Filed: June 5, 1996
    Date of Patent: June 25, 1996
    Assignee: Eli Lilly and Company
    Inventors: Sung Yong S. Cho, James D. Copp, Francis O. Ginah, Guy J. Hansen, Philip A. Hipskind, Bret E. Huff, Michael J. Martinelli, Michael A. Staszak, Roger W. Tharp-Taylor
  • Patent number: 5338851
    Abstract: This invention provides a process for the synthesis of cis-decahydroisoquinoline-3-carboxylic acids and provides intermediates in the synthesis thereof.
    Type: Grant
    Filed: March 31, 1993
    Date of Patent: August 16, 1994
    Assignee: Eli Lilly and Company
    Inventors: Bret E. Huff, Vien V. Khau, Michael J. Martinelli, Barry C. Peterson